Lisanti Capital Growth LLC Acquires New Position in Dyne Therapeutics, Inc. $DYN

Lisanti Capital Growth LLC bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 154,445 shares of the company’s stock, valued at approximately $3,021,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of DYN. Chung Wu Investment Group LLC bought a new position in Dyne Therapeutics in the 3rd quarter worth about $30,000. Strs Ohio bought a new position in Dyne Therapeutics in the 4th quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. grew its position in Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after purchasing an additional 1,109 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after purchasing an additional 7,697 shares during the last quarter. Finally, Prudential Financial Inc. bought a new position in Dyne Therapeutics in the 2nd quarter worth about $111,000. Institutional investors own 96.68% of the company’s stock.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 83,219 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the completion of the sale, the director directly owned 7,962 shares of the company’s stock, valued at $144,749.16. This represents a 91.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner bought 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $17.12 per share, with a total value of $42,800.00. Following the completion of the purchase, the director owned 18,000 shares of the company’s stock, valued at approximately $308,160. The trade was a 16.13% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders sold 1,559,462 shares of company stock valued at $29,814,746. Corporate insiders own 14.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on DYN. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. HC Wainwright decreased their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Chardan Capital restated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, Morgan Stanley reduced their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.00.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $17.37 on Friday. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The firm has a market cap of $2.87 billion, a P/E ratio of -5.39 and a beta of 1.08. The company has a 50 day moving average of $18.28 and a 200-day moving average of $18.39. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the business earned ($1.05) EPS. As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.